



## Prophylactic Anti-Emetic Effect of Dexamethasone and Metoclopramide on the Nausea and Vomiting Induced by Laparoscopic Cholecystectomy: A Randomized, Double Blind, Placebo-Controlled Trial

Ali Reza Khalaj<sup>1</sup>, Seyed Rohollah Miri<sup>2,\*</sup>, Mojdeh Porlashkari<sup>3</sup>, Amin Mohammadi<sup>4</sup>

<sup>1</sup> Department of Surgery, Shahed University, Tehran, IR Iran

<sup>2</sup> Department of Surgery, Tehran University of Medical Sciences, Tehran, IR Iran

<sup>3</sup> Department of Pathology, Tehran University of Medical Sciences, Tehran, IR Iran

<sup>4</sup> Tehran University of Medical Sciences, Tehran, IR Iran

\*Corresponding author: Seyed Rohollah Miri, Department of Surgery, Tehran University of Medical Sciences, Tehran, IR Iran, Tel.: +98-2122323252, Fax: +98-2166581657, E-mail: drsrmiri@yahoo.com.

### ABSTRACT

**Background:** Postoperative nausea and vomiting (PONV) is an unpleasant, distressing and frequent adverse effect after general anesthesia and surgery which has a high incidence in patients undergoing laparoscopic cholecystectomy. While none of the currently available antiemetic drugs are fully effective in all patients, it has been reported that dexamethasone is effective against emesis in patients undergoing general anesthesia.

**Objectives:** This study evaluates the prophylactic anti-emetic effect of dexamethasone in comparison with metoclopramide and placebo for the prevention of post-operative nausea and vomiting in patients undergoing elective laparoscopic cholecystectomy.

**Patients and Methods:** In Mostafa Khomeini hospital, a teaching hospital of Shahed University, Tehran, Iran, a randomized, double-blind and placebo-controlled study on 161 patients undergoing general anesthesia for elective laparoscopic cholecystectomy was run. One hundred sixty one patients (124 females and 37 males) requiring general anesthesia for laparoscopic cholecystectomy were studied. The dexamethasone group (n = 53) received dexamethasone 8mg IV, the metoclopramide group (n = 55) received metoclopramide 10mg IV and the placebo group (n = 53) received 2ml saline IV at the induction of anesthesia.

**Results:** In the current study, 26.4 %, 32.7 % and 52.8 % of patients reported vomiting in the dexamethasone, metoclopramide and placebo group ( $P \leq 0.001$ ), respectively. The total incidence of nausea and vomiting also reduced to 30.2% with dexamethasone in comparison with 49.1 % in metoclopramide group and 58.5 % in placebo group. ( $P \leq 0.001$ )

**Conclusions:** Dexamethasone 8mg is a better anti-emetic agent than metoclopramide for the prevention of post-operative nausea and vomiting after laparoscopic cholecystectomy.

**Keywords:** Vomiting; Dexamethasone; Cholecystectomy, Laparoscopic

▶ Article type: Research Article; Received: 03 Dec 2012; Accepted: 26 Jan 2013; Epub: 30 June 2013;

▶ Implication for health policy makers/practice/research/medical education:

This research demonstrated the significant efficacy of dexamethazone on post-operative nausea and vomiting comparison of metoclopramide.

▶ Please cite this paper as:

Khalaj AR, Miri SR, Porlashkari M, Mohammadi A. Prophylactic Anti-Emetic Effect of Dexamethasone and Metoclopramide on the Nausea and Vomiting Induced by Laparoscopic Cholecystectomy: A Randomized, Double Blind, Placebo-Controlled Trial. J Minim Invasive Surg Sci. 2013; 2(3): 18-22.

▶ Copyright © 2013, Minimally Invasive Surgery Research Center and Mediterranean and Middle Eastern Endoscopic Surgery Association.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## 1. Background

Postoperative nausea and vomiting (PONV) are unpleasant, distressing adverse effects after general anesthesia and surgery (1-3). The incidence of PONV is high in patients (53% - 72%) undergoing laparoscopic cholecystectomy (2, 3). It has been reported that dexamethasone is effective against emesis in patients undergoing chemotherapy, and also it has been recently reported to be effective in prevention of nausea and vomiting after surgery (4-6) and (7, 8). So this study was conducted as a randomized, double-blind and placebo-controlled trial to determine the effect of dexamethasone in the prevention of PONV in patients undergoing laparoscopic cholecystectomy.

## 2. Objectives

The current study aimed to evaluate the prophylactic anti-emetic effect of dexamethasone in comparison with that of metoclopramide and placebo for the prevention of post-operative nausea and vomiting in patients undergoing elective laparoscopic cholecystectomy.

## 3. Patients and Methods

Medical Ethic committee of Shahed University approved the study, and 161 patients (124 females and 37 males) undergoing general anesthesia for elective laparoscopic cholecystectomy in Mostafa Khomeini hospital during 2003-2005 were enrolled in a randomized, double-blind and placebo-controlled study. Patients with a history of motion sickness, intestinal diseases or the patients who had received antiemetic within 24 h before surgery, women who were pregnant or breastfeeding, and those who had evidence of hepatic dysfunction were excluded from the study. Patients were randomly allocated to receive dexamethasone 8 mg, metoclopramide 10m, or placebo (0.9% saline) intravenously immediately prior to the induction of anesthesia.

The anesthetic condition was standardized. Laparoscopic cholecystectomy was performed as a standard procedure with pre-operative cholangiography. The duration of the surgery, anesthesia, CO<sub>2</sub> insufflation and rate of cholangiography were recorded. Post-operative analgesia was provided by pethidine 25mg IM. During the first 24h after anesthesia, all episodes of post-operative PONV were recorded by direct questioning from nursing staff 7 times in the time of 0, 1 h, 2 h, 4 h, 8 h, 12 h and 24 h without the knowledge that which anti-emetic agents the patient had received, if he had received any. Nausea was defined as the subjectively un-pleasant sensation associated with awareness of the urge to vomit whereas vomiting was defined as the forceful expulsion of gastric contents from the mouth (9). Retching was not associated a separate entity and patients who experienced retching were classified as vomiting. Complete response was defined as the absence of nausea and vomiting throughout the study period. Patient data were analyzed through a one-way analysis of variances (ANOVA), students T test and chi-square test, where appropriate. A P-value of < 0.05 was considered significant. All values were expressed as Mean SD and number (%).

## 4. Result

After randomization, 53 patients were allocated to group 1 to receive dexamethasone, 55 patients to group 2 to receive metoclopramide and 53 patients to group 3 to receive normal saline. Patients' characteristics (age, weight and sex), information about operation (duration of anesthesia, surgery and rate of cholangiography as well as CO<sub>2</sub> insufflation) had no significant difference among the three groups (Table 1). No significant side-effects were found after the use of either dexamethasone or metoclopramide compared with that of normal saline.

**Table 1.** Patient Characteristics and Operative Information

	Dexamethasone (n = 53)	Metoclopramide (n = 55)	Placebo (n = 53)
Age, y, Mean ± SD	52.9 ± 15.04	52.38 ± 15.25	53.92 ± 16.23
Weight, Kg, Mean ± SD	70.47 ± 11.61	71.94 ± 10.33	70.88 ± 10.78
Sex, No.			
Female	41	43	40
Male	12	12	13
Duration of Anesthesia, min, Mean ± SD	121.69 ± 21.34	124.72 ± 21.04	118.58 ± 21.28
Duration of Surgery, min, Mean ± SD	89.52 ± 19.29	94.90 ± 20.01	87.83 ± 21.51
Duration of CO <sub>2</sub> insufflation, min, Mean ± SD	79.81 ± 18.88	85.63 ± 19.76	78.39 ± 21.36
Rate of Cholangiography, %	75.5	81.8	73.6

After the first 24 h following the anesthesia, PONV still occurred in 16% of patients in group 1, in 23.9% of group 2 and in 32.3% of group 3 respectively (Table 2). The total

incidence of nausea and vomiting during 24 h of observation was 30.2%, 49.1% and 58.5% in the 1st, 2nd and the 3rd group (P < 0.001), respectively.

**Table 2.** Occurrence of PNOV among Different Groups of Study

	Dexamethasone (n = 53)	Metoclopramide (n = 55)	Placebo (n = 53)	P value
<b>1<sup>st</sup> Hour After Surgery</b>				
<b>Nausea (+), No. (%)</b>	14 (26.4)	18 (32.7)	23 (43.49)	0.176
<b>Vomiting</b>				0.066
<b>No</b>	44 (83.0)	47 (85.5)	37 (69.8)	
<b>Once</b>	8 (15.1)	7 (12.7)	10 (18.9)	
<b>Twice or More</b>	1 (1.9)	1 (1.8)	6 (11.3)	
<b>2<sup>nd</sup> Hours After Surgery</b>				
<b>Nausea (+), No. (%)</b>	14 (26.4)	18 (32.7)	23 (43.49)	0.176
<b>Vomiting</b>				
<b>No</b>	45 (89.9)	40 (72.7)	29 (54.7)	
<b>Once</b>	8 (15.1)	10 (18.2)	14 (26.4)	
<b>Twice or More</b>	0 (0.0)	5 (9.1)	10 (18.9)	
<b>4<sup>th</sup> Hours After Surgery</b>				
<b>Nausea (+), No. (%)</b>	16 (30.2)	27 (49.1)	31 (58.5)	0.012 <sup>a</sup>
<b>Vomiting</b>				0.013 <sup>a</sup>
<b>No</b>	39 (73.6)	38 (69.1)	25 (47.2)	
<b>Once</b>	9 (17)	8 (14.5)	15 (28.3)	
<b>Twice or More</b>	5 (9.4)	9 (16.4)	13 (24.5)	
<b>8<sup>th</sup> Hours After Surgery</b>				
<b>Nausea (+), No. (%)</b>	10 (18.9)	23 (41.8)	27 (50.9)	0.002 <sup>a</sup>
<b>Vomiting</b>				0.002 <sup>a</sup>
<b>No</b>	47 (88.7)	37 (67.3)	31 (58.5)	
<b>Once</b>	4 (7.5)	9 (16.4)	10 (18.9)	
<b>Twice or More</b>	2 (3.8)	9 (16.4)	12 (22.6)	
<b>12<sup>th</sup> Hours After Surgery</b>				
<b>Nausea (+), No. (%)</b>	9 (17)	15 (27.3)	16 (30.2)	0.254
<b>Vomiting</b>				0.019 <sup>a</sup>
<b>No</b>	50 (94.3)	50 (90.9)	41 (77.4)	
<b>Once</b>	2 (3.8)	4 (7.3)	7 (13.2)	
<b>Twice or More</b>	1 (1.9)	1 (1.8)	5 (9.4)	
<b>24<sup>th</sup> Hours After Surgery</b>				
<b>Nausea (+), No. (%)</b>	0 (0)	3 (5.5)	3 (5.7)	0.216
<b>Vomiting</b>				0.610
<b>No</b>	53 (100)	54 (98.2)	52 (98.1)	
<b>Once</b>	0 (0)	1 (1.8)	1 (1.9)	
<b>Twice or More</b>	53 (100)	54 (98.2)	52 (98.1)	

<sup>a</sup> Statistically significant

## 5. Discussion

PONV is a distressing and frequent adverse effect after general anesthesia and surgery with high rate of occurrence after laparoscopic cholecystectomy to treat chole-

lithiasis (2, 3). However, Laparoscopic cholecystectomy is associated with shorter post-operative hospital stay and less post-operative pain and has become a widely used surgical technique (10). The physiological mecha-

nism of PONV has not been fully understood, although it seems that nitrous oxide, abdominal operations, female gender, laparoscopy and operation on the gastrointestinal tract have been involved. Some previous reports claimed that the anti-emetic effect of dexamethasone appeared to be equal or better than the antagonists of 5-HT<sub>3</sub> receptors such as ondansetron and granisetron (5, 11); However, due to the multifactorial origin of PONV, none of currently available antiemetic drugs are fully effective in all patients (6). Recently dexamethasone has also been reported to be effective in the prevention of nausea and vomiting after pediatric and gynecological surgery (7, 8). The current study shows that dexamethasone reduces PONV in patients undergoing elective laparoscopic cholecystectomy. It was also found that dexamethasone is significantly more effective than MPO in such patients. In the current experiment the incidence of PONV during the first 12h after anesthesia and the total incidence of PONV had significant reduction of 18.3% and 28.3 % with dexamethasone in comparison with placebo respectively. Both incidences were higher in MPO group. These findings supported the previous studies which implied the notion that dexamethasone had better effect than the other after surgery anti-emetics (12-15). The exact mechanism by which dexamethasone, a corticosteroid, exerts an anti-emetic action has not been fully understood. However, there have been some suggestions such as central or peripheral inhibition of the production or secretion of serotonin (6,9,13,16-23) by releasing endorphins (24) and central inhibition of synthesis of prostaglandins (16) or changes in the permeability of the blood brain barrier to serum proteins. Its anti-emetic action, at least in part, may be elicited via the blockage of corticosteroid receptors in the nucleus tractussolitarius of the CNS (8). Dexamethasone may also exert its anti-emetic action through some peripheral mechanisms (25, 26). Dexamethasone have strong anti-inflammatory effects and may significantly reduce inflammation around the surgical sites and does reduce the ascending parasympathetic impulses (Vagus) to the vomiting center and PONV(3,6,9,12,13,16-24,27). The etiology of PONV has not been precisely realized, but it is probably multifactorial (18). Dexamethasone was more effective when administered before induction (28). Risk factors such as a long period of carbon-dioxide insufflation (19), gall-bladder surgery, female sex (3, 20) and post-operative pain may contribute to these episodes (20, 21); since these risk factors may interfere with the interpretation of the study data they were controlled within the study design. The duration of anesthesia, surgery, CO<sub>2</sub> insufflation and the anesthetic drugs were similar among the three groups. In addition, after random patient selection, sex distributions among groups were similar. Therefore the difference in the occurrence of PONV among groups can be attributed to the tested

drugs. A wide dose range of dexamethasone (8-32 mg) has been used in the prophylaxis of emesis related to chemotherapy and after pediatric and gynecological surgeries (7, 26, 29). The effectiveness of small doses of dexamethasone (2.5 - 5 mg) in the prevention of PONV has already been validated (13). However, in a study performed by Víctor Contreras-Domínguez et al., the dose of 4 mg was used and they had not found dexamethasone to be superior to placebo (28). Since 8mg dose of dexamethasone has been the most frequently used dosage of dexamethasone in the previous similar studies, in the current study, a single bolus dose of 8 mg dexamethasone was administered and this could be the reason of this conflict. The inherent risks of dexamethasone include infection and adrenal suppression. However no report of complications associated with a single bolus of dexamethasone is reported so far (28). The frequent incidence of PONV has been reported to be 53-72% (12, 30,31). In the current study, the total incidence of PONV in the control group, without any prophylactic administration of antiemetic, was 58% which is compatible with the other studies. Since the postoperative pain and residual CO<sub>2</sub> in peritoneum are risk factors of PONV (1) it is better to measure them to make sure that they are the same between groups. In the current study, although postoperative pain was not measured, adequate analgesia was provided for all patients. As it can be seen in table 2 there was no significant difference between the study groups regarding other potential confounding factors. Also as it is mentioned above, laparoscopy is another risk factor and to avoid this potential source of bias all surgeries were done by one surgeon. Results of the current study indicated that prophylactic IV dexamethasone 8mg significantly reduces the incidence of PONV in patients undergoing laparoscopic cholecystectomy and that dexamethasone is more effective than metoclopramide and placebo without any important side effects. It can be concluded that the best way to reduce post-operative nausea and vomiting in patients who undergo laparoscopic cholecystectomy is the prophylactic administration of 8 mg of dexamethasone.

### Acknowledgements

None declared

### Authors' Contribution

None declared

### Financial Disclosure

None declared

### Funding/Support

None declared

## References

1. Bisgaard T, Klarskov B, Rosenberg J, Kehlet H. Factors determining convalescence after uncomplicated laparoscopic cholecystectomy. *Arch Surg*. 2001;**136**(8):917-21.
2. Koivuranta MK, Laara E, Ryhanen PT. Antiemetic efficacy of prophylactic ondansetron in laparoscopic cholecystectomy. A randomized, double-blind, placebo-controlled trial. *Anaesthesia*. 1996;**51**(1):52-55.
3. Fredman B, Jedeikin R, Olsfanger D, Flor P, Gruzman A. Residual pneumoperitoneum: a cause of postoperative pain after laparoscopic cholecystectomy. *Anesth Analg*. 1994;**79**(1):152-4.
4. Aapro MS, Alberts DS. Dexamethasone as an antiemetic in patients treated with cisplatin. *N Engl J Med*. 1981;**305**(9):520.
5. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research. *J Clin Oncol*. 1997;**15**(1):124-30.
6. Neseek-Adam V, Grizelj-Stojcic E, Rasic Z, Cala Z, Mrsic V, Smiljanic A. Comparison of dexamethasone, metoclopramide, and their combination in the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. *Surg Endosc*. 2007;**21**(4):607-12.
7. Pappas AL, Sukhani R, Hotaling AJ, Mikat-Stevens M, Javorski JJ, Donzelli J, et al. The effect of preoperative dexamethasone on the immediate and delayed postoperative morbidity in children undergoing adenotonsillectomy. *Anesth Analg*. 1998;**87**(1):57-61.
8. Liu K, Hsu CC, Chia YY. Effect of dexamethasone on postoperative emesis and pain. *Br J Anaesth*. 1998;**80**(1):85-6.
9. Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. *Anesthesiology*. 1992;**77**(1):162-84.
10. Rose DK, Cohen MM, Soutter DI. Laparoscopic cholecystectomy: the anaesthetist's point of view. *Can J Anaesth*. 1992;**39**(8):809-15.
11. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. The Italian Group for Antiemetic Research. *N Engl J Med*. 1995;**332**(1):1-5.
12. Elhakim M, Nafie M, Mahmoud K, Atef A. Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy. *Can J Anaesth*. 2002;**49**(9):922-6.
13. Wang JJ, Ho ST, Uen YH, Lin MT, Chen KT, Huang JC, et al. Small-dose dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy: a comparison of tropisetron with saline. *Anesth Analg*. 2002;**95**(1):229-32.
14. Splinter WM, Rhine EJ. Low-dose ondansetron with dexamethasone more effectively decreases vomiting after strabismus surgery in children than does high-dose ondansetron. *Anesthesiology*. 1998;**88**(1):72-5.
15. April MM, Callan ND, Nowak DM, Hausdorff MA. The effect of intravenous dexamethasone in pediatric adenotonsillectomy. *Arch Otolaryngol Head Neck Surg*. 1996;**122**(2):117-20.
16. Fredrikson M, Hursti T, Furst CJ, Steineck G, Borjeson S, Wikblom M, et al. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. *Br J Cancer*. 1992;**65**(5):779-80.
17. Aapro MS, Plezia PM, Alberts DS, Graham V, Jones SE, Surwit EA, et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. *J Clin Oncol*. 1984;**2**(5):466-71.
18. Livrea P, Trojano M, Simone IL, Zimatore GB, Logroscino GC, Pisicchio L, et al. Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. *J Neurol*. 1985;**231**(6):336-9.
19. Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Anti-emetic efficacy of prophylactic granisetron, droperidol and metoclopramide in the prevention of nausea and vomiting after laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled trial. *Eur J Anaesthesiol*. 1998;**15**(2):166-71.
20. Mraovic B, Jurisic T, Kogler-Majerich V, Sustic A. Intraperitoneal bupivacaine for analgesia after laparoscopic cholecystectomy. *Acta Anaesthesiol Scand*. 1997;**41**(2):193-6.
21. Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. *Anesth Analg*. 1994;**78**(1):7-16.
22. Kovac AL. Prevention and treatment of postoperative nausea and vomiting. *Drugs*. 2000;**59**(2):213-43.
23. Kashmiri Zu, Sheikh Z, Haider S. Injection dexamethasone in preventing postoperative nausea and vomiting: a comparison with placebo in the patients undergoing laparoscopic cholecystectomy. *J Coll Physicians Surg Pak*. 2006;**16**(11):689-92.
24. Bisgaard T, Klarskov B, Kehlet H, Rosenberg J. Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial. *Ann Surg*. 2003;**238**(5):651-60.
25. Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. *Anesth Analg*. 2000;**90**(1):186-94.
26. Wang JJ, Ho ST, Liu YH, Lee SC, Liu YC, Liao YC, et al. Dexamethasone reduces nausea and vomiting after laparoscopic cholecystectomy. *Br J Anaesth*. 1999;**83**(5):772-5.
27. Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. *Anesth Analg*. 2000;**91**(1):136-9.
28. Contreras-Dominguez V, Carbonell-Bellolio P. Prophylactic antiemetic therapy for acute abdominal surgery. A comparative study of droperidol, metoclopramide, tropisetron, granisetron and dexamethasone. *Rev Bras Anestesiol*. 2008;**58**(1):35-44.
29. Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. *N Engl J Med*. 1984;**311**(9):549-52.
30. Naguib M, el Bakry AK, Khoshim MH, Channa AB, el Gammal M, el Gammal K, et al. Prophylactic antiemetic therapy with ondansetron, tropisetron, granisetron and metoclopramide in patients undergoing laparoscopic cholecystectomy: a randomized, double-blind comparison with placebo. *Can J Anaesth*. 1996;**43**(3):226-31.
31. Iitomi T, Toriumi S, Kondo A, Akazawa T, Nakahara T. [Incidence of nausea and vomiting after cholecystectomy performed via laparotomy or laparoscopy]. *Masui*. 1995;**44**(12):1627-31.